期刊文献+

纤溶酶原激活物抑制物-1与动脉粥样硬化关系的研究 被引量:4

Study on relationship of plasminogen activator inhibitor-1 and atherosclerosis in rabbits.
原文传递
导出
摘要 目的通过对动脉粥样硬化(AS)兔血清和粥样硬化斑块中纤溶酶原激活物抑制物-1(PAI-1)表达的研究,探讨PAI-1在AS中的作用。方法16只雄性大耳白兔随机分为正常饮食组和高脂饮食组,每组8只,饲养16周。两组白兔均于0周、16周取耳缘静脉血,检测血清中PAI-1的水平;16周后处死,应用免疫组化方法检测PAI-1在主动脉粥样硬化斑块中的表达。结果正常饮食组和高脂饮食组0周血清中PAI-1水平差异无显著性(P>0.05);高脂饮食组16周后血清PAI-1水平较0周显著增加(P<0.01);免疫组化结果显示高脂饮食组主动脉壁PAI-1的表达明显高于对照组(P<0.01)。结论动脉粥样硬化的发生伴有血清和粥样斑块中PAI-1表达增加,PAI-1可能参与了AS的形成。 Objective To study the expression of plasminogen activator inhibitor -1 ( PAI-1 ) of the blood serum and plaques in atherosclerotic rabbits in order to explore the effect of PAI-1 on atherosclerosis ( AS ). Metbotis 16 male white rabbits were randomly divided into normal diet group and high cholesterol diet group (n = 8 for each). The rabbits were fed for 16 weeks. Blood was collected from the marginal vein of the ear in 0 and 16 weeks re- spectively in two groups. Concentration of PAI-1 was measured; After 16 weeks,the rabbits were sacrificed to investigate the expression of PAI-1 in aortic atherosclerosis by immunohistochemistry analysis. Results There were not obvious differences of PAI-1 in the normal diet group and the high-cholesterol diet group at 0 week (P 〉 0.05 ), obvious increment of PAI-1 in the high-cholestrol diet group after 16 weeks than 0 week ( P 〈 0.01 ) ; the higher expression of PAI-1 in cholesterol diet group was higher than that in control group ( P 〈 0.01 ). Conclusion PAI-1 expression is increased in blood serum and plaque , which is correlated with atherosclerosis, suggesting that PAI maybe involved in the formation of AS.
出处 《中国综合临床》 北大核心 2006年第7期577-579,共3页 Clinical Medicine of China
基金 吉林省科技厅资助课题(20050408)
关键词 动脉粥样硬化 纤溶酶原激活物抑制物-1 Atherosclerosis Plasminogen activator inhibitor -1
  • 相关文献

参考文献11

  • 1Olexa P,Exova M.Plasminogen activator inhibitor 1(PAI-1),chemic heart disease and diabetes mellitus[J].Vnitr Lek,2003,49(3):222-226.
  • 2潘志红,李东霞,张江蓉,王一尘,袁惠敏,刘芳.不同程度动脉粥样硬化症患者血浆内皮素和一氧化氮水平的研究[J].中国综合临床,2003,19(7):590-592. 被引量:13
  • 3Song R,Ricky YKM,Aubie A.Oxidative modification enhances lipoprotein(a)-induced overproduction of plasminogen activator inhibitor -1 in cultured vascular endothelial cells[J].Atherosclierosis,1997,128(2):1-10.
  • 4Douglas E,Vaughan MD.Angiotensin,fibrinolysis,and vascular homeostasis[J].Am J Cardiol,2001,87(Suppl):18-24.
  • 5黄芸,戴闺柱,冯宗忱,鲁成发,成蓓,王秋芬,聂福鼎,李景东.微粒化非诺贝特对高三酰甘油血症患者血管内皮功能的作用[J].临床心血管病杂志,2003,19(8):481-483. 被引量:3
  • 6Rerolle IP,Hertig A,Nguyen G,et al.Plas minogen activator inhibitor 1 is a potential target in renal fibrogenesis[J].KidneyInt,2000,58(5):1 841-1 850.
  • 7Chandler WL,Stratton JR.Laboratory evaluation of fibrinolysis in patients with a history of myocardial infarction[J].Am J Clin Pathol,1994,102(2):248-252.
  • 8Schneiderman J,Sawdey MS,Keeton MR,et al.Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotis human arteries[J].Proc Natl Acad Sci USA,1992,89(15):6 998-7 002.
  • 9Held C,Hjemdahl P,Rehnqvist N,et al.Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metroprolol:results from the angina prognosis study in Stockholm[J].Circulation,1997,95(10):2 380-2 386.
  • 10Haverkate F.Levels of haemostatic factors,arteriosclarosis and cardiovascular disease[J].Vase Pharmacol,2002,39(3):109-112.

二级参考文献14

  • 1中华心血管病杂志编辑委员会心血管药物对策专题组.心血管药物临床试验评价方法的建议.Ⅲ调血脂药[J].中华心血管病杂志,1998,26(1):9-11.
  • 2Hahmann H W, Bunte T, Hellwig N, et al. Progression and regression of minoreoronary arterial narrowings by quantitative angiography after fenofibrate therapy.Am J Cardiol, 1991, 67: 957--961.
  • 3Ericsson C G, Hamsten A, Nilsson J, et al. An angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet, 1996, 347: 849--853.
  • 4Celermajer D S,Sorensen K E,Gooch V M,et al.Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.Lancet,1992,340:1111—1115.
  • 5Grundy S M. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol,1998, 81:18B--25B.
  • 6Hackman A, Abe Y, Insull W, et al. Levels of soluble adhesion molecules in patients with dyslipidemia. Circulation, 1996, 93:1334--1338.
  • 7Marx N, Sukhova G K, Collins T, et al. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation, 1999, 99:3125--3131.
  • 8Andrews T C, Whitney E J, Green G, et al. Effect ofgemfibrozil + / -- niactin + / -- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels< 160mg/dl and high-density lipoprotein cholesterol levels<40mg/dl. Am J Cardiol,1997,80 : 831 -- 835.
  • 9Ross R.Atherosclerosis-an inflammatory disease[J],1999(02).
  • 10Yanagisawa M;Kurihara H;Kimura S.A novel potent vasoconstrictor peptide produced by vascular endothelial cells[J],1988(6163).

共引文献14

同被引文献47

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部